Primary treatment of acromegaly with high-dose lanreotide: a case series

肢端肥大症 兰瑞肽 医学 Pegvisomant公司 不利影响 外科肿瘤学 外科 经蝶手术 生长抑素 内科学 生长激素 胃肠病学 腺瘤 激素 垂体腺瘤
作者
Christian Wüster,Stefan Both,U. Cordes,Wael Omran,Róbert Reisch
出处
期刊:Journal of Medical Case Reports [BioMed Central]
卷期号:4 (1): 85-85 被引量:12
标识
DOI:10.1186/1752-1947-4-85
摘要

INTRODUCTION: The first-line treatment for acromegaly is transsphenoidal surgery. In approximately 50% of patients, however, a cure is not possible with surgery and alternatives are needed. Somatostatin analog therapy is the recommended first-line treatment in patients with such cases. Here we provide the first report of a high-dose lanreotide primary therapy in patients with acromegaly. CASE PRESENTATION: Six patients who were not suitable for surgery were given 60 mg of lanreotide (Autogel(R)) every four weeks. All patients were German nationals and Caucasian.When the response of our patients was unsatisfactory, the dose was increased sequentially to 90 mg every four weeks, 120 mg every four weeks, 120 mg every three weeks and 180 mg every three weeks. Treatment duration was 12 to 24 months. In all cases, the lanreotide dose was 120 mg every 4 weeks or higher. In five of our patients, growth hormone (GH) levels were successfully reduced (in three patients GH <2.5 ng/ml was achieved). Insulin-like growth factor 1 levels were normalized in three patients and decreased in two patients. One patient failed to show a biochemical response to lanreotide therapy or pegvisomant therapy.Tumor shrinkage or degeneration was observed in the five responding patients. No drug-related adverse events were noted. CONCLUSIONS: These results suggest that lanreotide at high doses of 120 mg every four weeks or more is an effective first-line therapy for patients with acromegaly that surgery alone cannot treat.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
科研通AI6.3的应助被执着盼海采纳,获得10
2秒前
躲进小楼完成签到,获得积分10
3秒前
123发布了新的文献求助10
3秒前
NexusExplorer的应助被自由的秋灵采纳,获得10
3秒前
4秒前
ldz发布了新的文献求助10
5秒前
XIAOGONG发布了新的文献求助10
5秒前
Roselle完成签到,获得积分10
5秒前
5秒前
5秒前
汉堡包的应助被好的呢采纳,获得10
5秒前
赘婿的应助被好的呢采纳,获得10
5秒前
5秒前
搜集达人的应助被好的呢采纳,获得10
6秒前
咕噜完成签到,获得积分10
6秒前
bkagyin的应助被好的呢采纳,获得10
6秒前
CipherSage的应助被好的呢采纳,获得10
6秒前
6秒前
orixero的应助被好的呢采纳,获得10
6秒前
jing发布了新的文献求助10
7秒前
lvzhechen发布了新的文献求助10
7秒前
秀秀完成签到,获得积分10
8秒前
9秒前
9秒前
CipherSage的应助被drsong采纳,获得10
9秒前
chuanchuan发布了新的文献求助10
9秒前
10秒前
传奇3的应助被杨子墨采纳,获得10
10秒前
Yin完成签到,获得积分20
10秒前
li完成签到,获得积分10
10秒前
10秒前
柒年发布了新的文献求助10
11秒前
tulip发布了新的文献求助10
11秒前
孙兆楠发布了新的文献求助10
11秒前
12秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193599
求助须知:如何正确求助?哪些是违规求助? 9579723
关于积分的说明 21867157
捐赠科研通 7793198
什么是DOI,文献DOI怎么找? 3437314
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484193